RxDoctor Payments Data

Barbara Allis, MD

Neurology · Huntington, NYNPI 1659386324

Payments from drug & device makers

$2,533in general payments, 2019–2025

Across 48 payments — averaging $52.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Teva Pharmaceuticals USA, Inc.$455
  • Boston Scientific$363
  • Abbott$167
  • Axsome Therapeutics, Inc.$125
  • EMD Serono, Inc.$118
  • plus $302 from 4 others

What the payments were for

  • Food & beverage$2,42196%
  • Education$1124%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,533 in reported general payments places this provider in the 55th percentile of 1,623 neurology providers in New York.

See all neurology providers in New York

Medicare billing

Part B allowed, 2024
$250,971
Medicare patients
430
Services billed
19,204

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MysolinePrimidone12$70,773
Zolmitriptan82$47,347
UbrelvyUbrogepant29$35,675
Emgality PenGalcanezumab-Gnlm42$32,616
OxycontinOxycodone Hcl18$22,234
Nurtec OdtRimegepant Sulfate16$21,920
Sumatriptan Succinate111$17,973
KeppraLevetiracetam12$9,688
Aimovig AutoinjectorErenumab-Aooe13$9,489
VyvanseLisdexamfetamine Dimesylate16$8,088
Butalbital-Acetaminophen-CaffeButalb/Acetaminophen/Caffeine85$7,613
Eletriptan HbrEletriptan Hydrobromide60$5,716
Carbidopa-LevodopaCarbidopa/Levodopa166$4,397
Gabapentin150$3,038
AmantadineAmantadine Hcl33$3,021

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy$1,004$35,67529 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,623 neurology providers in New York.

Other neurology in Huntington

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →